Full Text
EE63 Assessing the Socioeconomic Value of Ocrelizumab Subcutaneous for Treating Relapsing Multiple Sclerosis in the Evolving Treatment Landscape in the United Kingdom

Abstract

Authors

Nahida Choudhury Katya Galactionova

Back to Volume 28, Supplemental Issue 12S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×